OvaScience Inc (NASDAQ:OVAS) Gains Momentum on news of AUGMENT birth Print
By Josh Gee   
Thursday, 07 May 2015 15:30

Global fertility company OvaScience Inc (NASDAQ:OVAS) has confirmed one of the first patients who got AUGMENT treatment have given birth to healthy baby boy in Toronto, Ontario, Canada.

 

The mother spoke about the struggles before getting the treatment and said that the couple was positive on the treatment helping others suffering from poor egg health. Egg health is the main factor in female fertility.

Even though a number of factors are responsible for egg health, having appropriate levels of energy-producing mitochondria in the egg is vital for healthy fertilization as well as embryo development.

The treatment is made for improving health of woman’s existing eggs along with increasing IVF procedure as it uses energy-producing mitochondria from woman’s own egg. The AUGMENT treatment is not there in US currently.

Marjorie E. Dixon, M.D.C.M., F.R.C.S.(C), Medical Director at First Steps Fertility, Assistant Professor of Reproductive Endocrinology and Infertility at the University of Toronto, opined that one expects to witness unhealthy egg as women age, however a lot of younger women have poor egg health for a number of reasons.

 

Dixon added that he was surprised on discovering that the mothers eggs along with embryo quality was poor and that he was glad on offering the AUGMENT treatment to the couple for having their own biological child.

 

Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, opined that the mission of the firm is bringing better treatments for women in helping to build their families.

Robert F. Casper, M.D., F.R.C.S.(C), Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital,Toronto, and Medical Director of TCART Fertility Partners, stated that the clinic was the first one to give the treatment in Canada. He added that the success of IVF depends on many factors but most fertility experts opine that embryo and egg quality are key prognostic indicators.

 

Shares of the company are up 5.60% to $25.86, although off session high of $28.62.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!